Drug Profile
Irofulven - Lantern Pharma
Alternative Names: 6-HMAF; 6-hydroxymethylacylfulvene; E 7850; HMAF; Irofulven-1; LP 100; MGI 114Latest Information Update: 08 Jul 2023
Price :
$50
*
At a glance
- Originator University of California, San Diego
- Developer Allarity Therapeutics; Dainippon Sumitomo Pharma; Eisai Co Ltd; Lantern Pharma
- Class Antineoplastics; Cyclopropanes; Indenes; Sesquiterpenes; Small molecules; Spiro compounds
- Mechanism of Action Alkylating agents; Apoptosis stimulants; DNA synthesis inhibitors; RNA polymerase II inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Prostate cancer
- Preclinical Solid tumours
- Discontinued Cancer; Liver cancer; Ovarian cancer; Pancreatic cancer; Thyroid cancer
Most Recent Events
- 08 Jul 2023 Preclinical trials in Solid tumours in USA (unspecified route), prior to June 2023
- 02 Jun 2023 Pharmacodynamics data from a preclinical trial in Solid tumour presented at 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 15 Mar 2023 Lantern Pharma terminates the phase II trial in Prostate cancer (Hormone refractory, Combination therapy, Second-line therapy or greater, Metastatic disease) in Denmark (IV) due to the reason to allow the focus of LP-100-directed resources on positioning the molecule for development in earlier lines of therapy with potentially larger market opportunities (NCT03643107) (EudraCT2017-003549-72)